Is Nurix Therapeutics, Inc. (NRIX) Halal?
Shariah Screening — 5 Standards
Based on financial data from November 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.6% / 30% | 38.2% / 30% | 0.0% / 30% | 26.16% / 5% | ✗ NOT HALAL |
| DJIM | 3.6% / 33% | 38.2% / 33% | 0.0% / 33% | 26.16% / 5% | ✗ NOT HALAL |
| MSCI | 8.1% / 33% | 86.2% / 33% | 0.0% / 33% | 26.16% / 5% | ✗ NOT HALAL |
| S&P | 3.6% / 33% | 38.2% / 33% | 0.0% / 33% | 26.16% / 5% | ✗ NOT HALAL |
| FTSE | 8.1% / 33% | 86.2% / 33% | 0.0% / 50% | 26.16% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -277.4% | |
| Operating Margin | -612.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -49.6% | |
| Return on Assets (ROA) | -26.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$249M |
| Free Cash Flow | -$263M |
| Total Debt | $56M |
| Debt-to-Equity | 10.3 |
| Current Ratio | 7.0 |
| Total Assets | $688M |
Price & Trading
| Last Close | $15.53 |
| 50-Day MA | $16.31 |
| 200-Day MA | $13.59 |
| Avg Volume | 1.1M |
| Beta | 2.0 |
|
52-Week Range
$8.18
| |
About Nurix Therapeutics, Inc. (NRIX)
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Nurix Therapeutics, Inc. (NRIX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Nurix Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Nurix Therapeutics, Inc.'s debt ratio?
Nurix Therapeutics, Inc.'s debt ratio is 3.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 8.1%.
What are Nurix Therapeutics, Inc.'s key financial metrics?
Nurix Therapeutics, Inc. has a market capitalization of $1.5B, and revenue of $84M. Return on equity stands at -49.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.